BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
BridgeBio Oncology Therapeutics (BBOT) had its price target raised by HC Wainwright from $27.00 to $29.00. They now have a "buy" rating on the stock.
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
BBOT to Participate in Upcoming Investor Healthcare Conferences
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)